Trial Search Results

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Amgen

Stanford Investigator(s):

Intervention(s):

  • Drug: Rituximab
  • Drug: Epratuzumab

Phase:

N/A

Eligibility


Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mayita Romero
6507256452